News: CBE

Lynden A. Archer, the James A. Friend Family Distinguished Professor in Engineering, has been named the Joseph Silbert Dean of Engineering for a five-year term beginning July 1. Read more

Prof. Lynden Archer will be featured in the "Did you know ..." section on Wikipedia's main page and the Archer biographical article is now part of "queue 5:" https://en.wikipedia.org/wiki/Wikipedia:Recent_additions#2_June_2020 Prof. Archer's Wikipedia page can be found here: ( https://en.wikipedia.org/wiki/Lynden_Archer) Read more

The book titled, “Wall of Wonder,” includes ChemE alumni Karen Havenstrite (B.S. 2005), Ann Lee (PhD 1983), and Iyore Olaye (B.S. 2016). Read more

Cornell researchers are already making strides against COVID-19. The Cornell faculty boasts world-class virologists, such as Diego Diel, Population Medicine and Diagnostic Sciences, and Hector Aguilar-Carreno, Microbiology and Immunology. Cornell is also home to renowned coronavirus experts Susan Daniel, Chemical and Biomolecular Engineering, and Gary Whittaker, Microbiology and Immunology. Read more

Read more

“When we had to shut down our lab, we wanted to see what we could do with our expertise in systems engineering to help the public and provide timely information,” said Fengqi You, the Roxanne E. and Michael J. Zak Professor in Energy Systems Engineering, who is leading the effort. “We’re viewing this as a citizen science project, but one where accuracy and primary data are paramount.” Read more

A biomanufacturing company spun out of Cornell research is seeking to rapidly translate an antibody therapy against COVID-19 by using cell-free biotechnology based on glycoengineered bacteria. And it could scale up the production 10 times faster than conventional methods. The company, SwiftScale Biologics, was co-founded by Matt DeLisa, the William L. Lewis Professor of Engineering in the Robert F. Smith School of Chemical and Biomolecular Engineering, and his longtime collaborator, Michael Jewett, a professor of chemical and biological engineering at Northwestern University. Read more

Researchers from Cornell University have identified a possible target for antiviral treatment for COVID-19. The researchers initially set out to analyze the structure and characteristics of SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus), with a focus on the spike protein – specifically the fusion peptide – that allows these viruses to infect cells by transferring their genome. As the current pandemic escalated, the researchers compared the biological sequences of the fusion peptides of SARS-CoV to SARS-CoV-2, the virus that... Read more

Bob Langer, ChemE '70, co-founder of Moderna Therapeutics, a company that develops treatments that leverage specialized transporter molecules in cells known as messenger RNAs. Messenger RNAs bring instructions from genes to the cellular machinery that makes proteins. By creating specially modified mRNA, Moderna believes it can develop therapies to treat and prevent a number of diseases in humans. http://news.mit.edu/2020/mit-companies-covid-19-0326 Read more

Bob Langer, ChemE '70, co-founder of Moderna Therapeutics, a company that develops treatments that leverage specialized transporter molecules in cells known as messenger RNAs. Messenger RNAs bring instructions from genes to the cellular machinery that makes proteins. By creating specially modified mRNA, Moderna believes it can develop therapies to treat and prevent a number of diseases in humans. http://news.mit.edu/2020/mit-companies-covid-19-0326 Read more